A study showed that the first-generation ACEI drug captopril significantly inhibited the expression of inflammatory factors such as CXCL8 and IL6, ameliorating the inflammatory response and apoptosis associated with SARS-CoV-2, which may help guide the clinical management of COVID-19-associated cardiac fibers (Huang X. et al., 2023). Here, IL6 is linked to COVID-19.